I'm a big fan of everything in the pipeline except eltoprazine.

Doing what I do, it's tough for me to get excited about it. I do think it brings value and will make money, but it is no blockbuster. Getting approval for several indications would be great. It's a good building block, but I do not see anyway that it gets expedited by getting orphan status.

We'll see though.